How Long Does Antidepressant Discontinuation Syndrome Last?

Antidepressant discontinuation syndrome usually lasts 1 to 2 weeks, with symptoms most often beginning 2 to 4 days after the medication is stopped or sharply reduced, but a meaningful minority still have symptoms past 2 months. Some people experience symptoms for several months, and rare cases last much longer.

You may be reading this after a missed dose, a difficult taper, or a morning when dizziness, nausea, insomnia, irritability, or electric-shock sensations appeared without warning. Many people expect their original depression or anxiety to return first. Instead, they notice a distinctly physical and sensory reaction that starts soon after the dose changes.

The honest answer to how long antidepressant discontinuation syndrome lasts has two parts. The common course is brief and improves within a couple of weeks. The less common course can last many weeks or months, especially when the medication has a short half-life, treatment has continued for a long time, or the dose was reduced too quickly. Neither experience should be dismissed.

When the Brain Notices the Dose Is Gone

A 34-year-old office manager stopped taking paroxetine after following a short taper. Three days after her final tablet, she stood on a train platform and began rocking because the ground seemed to move beneath her. When she turned her head, brief electric sensations flickered through her head. Nausea rose into her throat, and she had trouble deciding whether she was about to faint or become sick.

She had expected sadness, worry, or loss of motivation. She hadn't expected dizziness, brain zaps, and nausea arriving together within days.

That timing matters. Most discontinuation symptoms begin 2 to 4 days after stopping or sharply reducing an antidepressant, according to a clinical review of the syndrome (clinical review of antidepressant discontinuation symptoms). Symptoms often become most disruptive during the first week. For most patients, the acute episode settles within 1 to 2 weeks, although the range is wider than many medication handouts suggest.

A person may have one dominant symptom, such as disequilibrium, or a cluster that includes insomnia, headache, sensory disturbances, gastrointestinal upset, irritability, and flu-like feelings. Brain zaps can be especially alarming. They're generally described as brief electrical or shock-like sensations, often triggered by eye or head movement. Patients looking for a plain-language explanation may find this guide to brain zaps useful, but persistent or severe symptoms still deserve clinical review.

The practical point: A rapid onset after a dose change, especially with dizziness or sensory symptoms, often points toward discontinuation rather than an immediate return of the original disorder.

The short course is typical, not universal. Evidence syntheses describe substantial variation, including people whose symptoms last beyond 2 weeks, cases extending past 8 weeks, and a small group with symptoms lasting months or longer (systematic review of duration and severity). The duration question therefore has a well-documented answer for many individuals and a much less tidy answer for the long tail.

What Antidepressant Discontinuation Syndrome Actually Is

Antidepressant discontinuation syndrome is a physiologic withdrawal pattern that can occur when the brain adapts to an antidepressant and the medication is removed too quickly. SSRIs, SNRIs, and some older antidepressants influence serotonergic, noradrenergic, or cholinergic signaling. After sustained exposure, the nervous system adjusts to that pharmacologic environment. A sudden reduction can leave the system temporarily out of balance while it readapts.

This process is not the same as classical addiction. Antidepressant discontinuation generally doesn't involve compulsive drug-seeking, intoxication, or a reward-driven pattern. Physical dependence, however, can occur without addiction, and physical symptoms after stopping are real.

A 2025 meta-analysis in JAMA Psychiatry examined withdrawal-related adverse events across randomized trials and used validated measures to help separate discontinuation symptoms from depressive relapse. The most common symptom during the first two weeks was dizziness, and stopping antidepressants wasn't associated with depressive symptoms in that analysis (2025 JAMA Psychiatry meta-analysis). Dizziness is clinically useful because it is much more characteristic of discontinuation than of ordinary depressive relapse.

Three patterns can look similar

Discontinuation syndrome usually begins soon after a dose reduction or cessation. The symptoms often feel physical or sensory: dizziness, electric-shock sensations, nausea, headache, tingling, insomnia, irritability, and flu-like malaise.

Relapse is the return of the underlying depression or anxiety disorder. It more often develops over time and centers on symptoms such as persistent low mood, loss of interest, hopelessness, escalating worry, or suicidal thinking. Withdrawal can include emotional volatility, so the distinction isn't always obvious.

Rebound means the original symptoms return with unusual intensity, sometimes beyond the person's previous baseline. Rebound anxiety, for example, may feel more intense than the anxiety that led to treatment.

Feature	Discontinuation Syndrome	Relapse	Rebound
Typical timing	Soon after a dose reduction or cessation	Often develops over weeks or longer	Original symptoms return abruptly and more intensely
Common features	Dizziness, sensory symptoms, nausea, insomnia, flu-like feelings	Low mood, anhedonia, hopelessness, anxiety	Exaggerated return of the original condition
Symptom pattern	Often fluctuates and may improve gradually	Usually persists or worsens without treatment	Strong recurrence of familiar symptoms
Clinical response	May improve after a carefully supervised dose adjustment	May require treatment for the underlying disorder	May settle as the nervous system stabilizes or need targeted care

Some patients also explore nonprescription approaches for mood, including the CBD and depression promising area of study from HempWell USA. CBD shouldn't be used as a substitute for evaluating withdrawal, relapse, medication interactions, or safety concerns with a qualified clinician.

The Timeline From First Symptom to Last

A fixed answer such as “one to two weeks” misses the range clinicians see. Systematic reviews found mean durations of 5 days, 10 days, 43 days, and 79 weeks across different studies. The variation reflects differences in medication, patient population, taper method, and study design (evidence synthesis on antidepressant withdrawal duration).

Phase one, acute onset

Symptoms commonly begin 2 to 4 days after a dose reduction or cessation. Dizziness, nausea, imbalance, brain zaps, sleep disruption, and irritability may arrive together. Some patients notice only mild changes. Others develop sensory symptoms severe enough to interfere with work, walking, or driving.

Phase two, acute resolution

Milder cases in the literature had mean durations around 5 days, while another study reported a mean of 10 days. Many patients improve during the first two weeks, particularly after gradual dose reductions or with medications that leave the body more slowly. Recovery can fluctuate. A patient may feel better for a day, then experience another wave of dizziness or insomnia.

Phase three, prolonged withdrawal

A subgroup remains symptomatic for several weeks. One heterogeneous body of evidence reported a mean duration of 43 days among people whose symptoms continued beyond the acute window. Abrupt cessation, repeated dose changes, and sharper changes in medication concentration may contribute to these longer courses.

Phase four, protracted symptoms

Published case-series data reported a mean of 79 weeks in a small subset meeting criteria for post-acute withdrawal. This does not predict the course for most patients. It does show why a short standard answer can be misleading for people whose symptoms occur in waves, with partial improvement followed by renewed dizziness, sleep problems, anxiety, or sensory disturbances.

The long tail reflects heterogeneity, not inevitability. Receptor adaptation, pharmacokinetics, prior treatment history, and individual biology can affect recovery. The AloeCure supplement timeline may help explain why changes from supplements can be gradual, but supplements do not provide a validated method for predicting or shortening antidepressant withdrawal.

Why Some Medications Take Longer to Leave Than Others

The medication's half-life strongly influences how quickly symptoms begin and how sharply they appear. A short half-life means the drug level can fall quickly after a missed dose or reduction. A longer half-life creates a slower decline, which may make the transition less abrupt.

Fluoxetine is the major contrast. Its active metabolite remains in the body for a longer period, so the medication often produces a slower, steadier reduction in pharmacologic effect. By comparison, paroxetine, venlafaxine, and duloxetine can produce earlier symptoms because their active compounds leave the system more quickly. The exact duration still depends on the taper and the individual.

Medication	Class	Half-life	Withdrawal risk
Fluoxetine	SSRI	4 to 6 days for the active metabolite window	Generally lower and slower onset
Sertraline	SSRI	Variable by patient	Moderate and variable
Escitalopram	SSRI	Variable by patient	Moderate and variable
Paroxetine	SSRI	Approximately 21 hours	Higher, often earlier onset
Venlafaxine	SNRI	Approximately 5 hours	Higher, often rapid onset
Duloxetine	SNRI	Approximately 12 hours	Significant and variable
Desvenlafaxine	SNRI	Variable by patient	Variable
Clomipramine	Tricyclic antidepressant	Variable by patient	Can be clinically significant
Other tricyclics	Tricyclic antidepressants	Variable by medication	Depends on the specific drug and taper

The half-life figures and the relationship between pharmacokinetics and discontinuation are summarized in clinical deprescribing guidance (SSRI and SNRI deprescribing guide). That guidance commonly recommends a taper lasting at least 4 weeks, while some patients need a longer plan.

A medication can be out of the bloodstream while the nervous system is still readjusting. “Longer to leave” refers to both elimination and the brain's return toward its prior signaling baseline.

The drug class doesn't determine the outcome by itself. A person taking paroxetine may have a manageable course with a carefully designed taper, while someone taking an apparently easier medication may struggle after an abrupt stop. For a more focused clinical comparison, see paroxetine versus fluoxetine.

Personal Factors That Stretch or Shorten the Course

Two people can take the same antidepressant and follow similar schedules yet have different withdrawal experiences. The most useful approach is to examine the variables that can be changed before the next dose reduction.

Taper speed and dose design

A linear taper removes the same milligram amount at each step. A hyperbolic taper reduces a percentage of the current dose, so the cuts become smaller as the dose gets lower. For some long-term users, reductions of 10% every 2 to 4 weeks are used as a starting framework, with adjustments based on symptoms. The exact plan must be individualized.

A person who has taken an antidepressant for years may need more time than someone who used it briefly. Longer exposure can mean more time for the nervous system to adapt, although treatment duration alone doesn't predict the entire course.

Medication and metabolism

The starting dose, half-life, formulation, and the person's metabolism all matter. Pharmacogenomic testing, including CYP450 information, may help explain why one patient has unusually high exposure or strong side effects, but testing doesn't give a precise withdrawal calendar. Age, pregnancy, anxiety disorders, and concurrent medications can also alter the clinical picture.

Alcohol and benzodiazepines deserve particular care. They may mask anxiety or insomnia temporarily, complicate symptom interpretation, or add sedation and coordination problems. Pregnancy introduces additional medication and safety considerations, so stopping or changing an antidepressant without obstetric and psychiatric input isn't appropriate.

A previous difficult taper is important clinical information, not a sign of weakness. If a person had severe symptoms after a prior reduction, the next plan should usually proceed more cautiously, with smaller changes and longer observation between steps. Genomind testing may be discussed when medication response or metabolism is unusually difficult to interpret, but it shouldn't be treated as a standalone predictor of withdrawal duration.

Evidence-Based Ways to Shorten the Experience

The safest way to shorten the overall experience is usually to avoid creating a severe withdrawal episode in the first place. A gradual, symptom-paced taper may take longer on the calendar, but it can reduce the chance that each dose reduction produces a destabilizing wave.

Build the taper around the current dose

A hyperbolic plan uses progressively smaller reductions as the dose becomes lower. For a long-term user, a clinician may consider a reduction of 10% every 2 to 4 weeks, then slow the schedule if symptoms accumulate. A linear schedule can work for some people, but fixed cuts become proportionally larger at low doses.

If symptoms become severe, temporary reinstatement of the last tolerated dose may be considered. The usual clinical logic is to stabilize first, then restart with smaller reductions. Reinstatement isn't a failure. It's a way to regain control of a taper that moved faster than the nervous system could tolerate.

Treat the symptoms without obscuring the picture

Ginger may help some people with nausea, while adequate caloric intake and hydration can prevent weakness from compounding the withdrawal experience. Sleep aids or a short course of a benzodiazepine may be appropriate in selected cases, but only when clinically indicated. Sedating medications can impair coordination, interact with alcohol or other drugs, and make it harder to tell whether the underlying syndrome is improving.

A daily symptom diary should record the dose, sleep, dizziness, nausea, sensory symptoms, anxiety, mood, and major stressors. That record helps distinguish a temporary wave from a steady deterioration and gives the prescriber information that memory often misses. Guidance on a structured medication reduction plan is also available in this overview of deprescribing Zoloft.

https://www.youtube.com/embed/O2Fck90X7Z4

Contact a clinician promptly for persistent suicidal ideation, hallucinations, mania, severe autonomic instability, or symptoms that continue beyond 8 weeks. Those signs require reassessment rather than an attempt to push through alone. Florida residents seeking follow-up can arrange a telepsychiatry medication review, and Refresh Psychiatry & Therapy states that medication reviews are conducted within 48 hours of contact for Florida residents.

Florida Patient Questions and How to Reach Us

Can a taper be supervised over video

For many Florida residents, yes. A video appointment can cover the medication history, current dose, prior taper attempts, withdrawal symptoms, sleep, mood, substance use, medical conditions, and safety concerns. The clinician can then create a staged plan, discuss available formulations, review the symptom diary, and adjust the schedule at follow-up.

Telepsychiatry works best when the patient has the medication bottle or prescription record available and can describe exactly when each reduction occurred. Bring a list of all medications, supplements, alcohol or benzodiazepine use, previous diagnoses, and any history of suicidal thinking, mania, or psychosis. A clinician may also need to coordinate with a primary-care doctor, therapist, pharmacist, or obstetric clinician.

Refresh Psychiatry & Therapy provides HIPAA-compliant telepsychiatry across Florida. Its deprescribing psychiatrist resource explains how medication reduction can be incorporated into psychiatric care rather than handled as an isolated prescription change.

Is it safe to drive while symptomatic

Don't drive if dizziness, blurred vision, imbalance, sedation, confusion, or brain zaps interfere with attention or reaction time. Even when discontinuation symptoms aren't medically dangerous, they can make a familiar task less predictable. A patient who feels the train platform moving, has trouble walking straight, or experiences sudden sensory jolts should arrange another way to travel.

If symptoms are mild, discuss driving with the treating clinician rather than relying on a general rule. The answer depends on the symptom, its timing, other medications, sleep, alcohol use, and whether the person can remain alert and coordinated. Avoid combining withdrawal symptoms with alcohol or sedating medication before driving.

How can I tell withdrawal from depressive relapse

Start with timing. Symptoms that appear within days of a dose reduction, especially dizziness, nausea, electric-shock sensations, imbalance, headache, insomnia, or flu-like feelings, are more consistent with discontinuation. Depressive relapse tends to center on persistent low mood, loss of interest, hopelessness, or suicidal thinking and may develop differently from the physical cluster.

The distinction isn't always clean. Anxiety and sleep disruption can occur in both conditions, and withdrawal can make a person feel emotionally raw. Track symptoms daily and seek a clinical review if the pattern is worsening, if mood symptoms dominate, or if there is any concern about safety.

A same-week reassessment is appropriate when symptoms persist beyond 8 weeks, when the diagnosis remains uncertain, or when the taper has repeatedly failed. Patients shouldn't endure months of disabling symptoms or restart medication without discussing the trade-offs. A review can consider holding the current dose, returning to the last tolerated dose, changing the taper rate, evaluating relapse, or looking for another medical explanation.

Refresh Psychiatry & Therapy offers statewide Florida telepsychiatry for adults, children, and adolescents, with psychiatric evaluations, medication management, therapy, pharmacogenomic analysis, and deprescribing when clinically appropriate. Patients should prepare their medication list, treatment timeline, symptom diary, pharmacy details, insurance information, and goals for stopping or changing treatment. The practice accepts Aetna, United Healthcare and UHC, Cigna, Blue Cross Blue Shield, Humana, Tricare, UMR, and Oscar insurance plans.

This blog is for informational purposes only and does not constitute medical advice. Please consult a qualified mental health professional for personalized guidance.

---

Refresh Psychiatry & Therapy offers Florida telepsychiatry evaluations, medication management, therapy, and individualized antidepressant tapering support when discontinuation is appropriate. Visit Refresh Psychiatry & Therapy or call (954) 603-4081 to schedule your evaluation. We accept Aetna, United Healthcare/UHC, Cigna, Blue Cross Blue Shield, Humana, Tricare, UMR, and Oscar insurance plans.